SCHEMBL6522802

SCHEMBL6522802

Cc1cc(Nc2cc3ccn(CCO)c(=O)c3c(NC(C)(C)CO)n2)ncc1Cl

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.36
TYK2 P29597 3/20 0.35
GRM2 Q14416 11/20 0.34
BCL6 P41182 2/20 0.33
NCOR2 Q9Y618 2/20 0.33
MAP2K1 Q02750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158927 0.90 SYK (0.41) SYKTYK2BCL6NCOR2
SCHEMBL6518376 0.90 TYK2 (0.42) SYKTYK2GRM2MAP2K1
SCHEMBL12797186 0.86 SYK (0.38) SYKTYK2BCL6NCOR2
SCHEMBL1158485 0.85 SYK (0.40) SYKTYK2MAP2K1
SCHEMBL1158713 0.83 SYK (0.54) SYKGRM2
SCHEMBL1159049 0.82 SYK (0.41) SYKGRM2BCL6NCOR2
SCHEMBL1158872 0.80 TYK2 (0.37) SYKTYK2BCL6NCOR2
SCHEMBL1158907 0.79 TYK2 (0.43) SYKTYK2
SCHEMBL1159077 0.77 SYK (0.42) SYKTYK2GRM2MAP2K1
SCHEMBL1158393 0.77 SYK (0.42) SYKTYK2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885TYK2 35/4885GRM2 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.